The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have received a £2 million funding boost from Wellcome to advance the regulation and evaluation of digital mental health technologies in the UK. This additional support, running until Autumn 2028, will enable the agencies to continue developing clear, proportionate guidance for tools such as symptom-tracking apps, AI-powered assessments, and virtual reality therapies, ensuring they are safe, effective, and evidence-based. The initiative aims to enhance public trust and support responsible innovation in the rapidly growing digital mental health sector.
Digital mental health technologies are increasingly integrated into NHS services and everyday life, offering benefits in managing conditions such as depression, anxiety, and stress. However, research indicates that many users are unaware of safety reporting mechanisms like the Yellow Card scheme, highlighting the need for clearer guidance. Since its launch in 2023, the programme has worked closely with people with lived experience, mental health specialists, developers, and international partners to establish risk-proportionate regulation and reliable evaluation standards.
The next phase of the programme will focus on key initiatives, including establishing a digital mental health technology AI airlock, exploring international mutual recognition for regulatory standards, improving the quality and evidence of available technologies, and addressing challenges in transferring evidence across borders. For the public and clinicians, these measures will provide clearer information about the safety, functionality, and evidence behind digital mental health tools. For developers, the framework will support innovation while ensuring adherence to robust safety standards.
Lawrence Tallon, Chief Executive of the MHRA, emphasized the importance of giving users confidence in digital mental health tools while facilitating responsible innovation. Professor Miranda Wolpert, Director of Mental Health at Wellcome, highlighted that the partnership with MHRA and NICE will help bring safer and more effective early intervention solutions for anxiety, depression, and psychosis into wider use, fostering collaboration between regulators and developers and strengthening global regulatory frameworks.
